David L. Kemmerly - 29 Mar 2022 Form 4 Insider Report for AMEDISYS INC (AMED)

Signature
/s/ Jennifer R. Guckert, pursuant to a power of attorney
Issuer symbol
AMED
Transactions as of
29 Mar 2022
Net transactions value
-$443,285
Form type
4
Filing time
04 Apr 2022, 20:57:33 UTC
Previous filing
22 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMED Common Stock Sale $3,503 -20 -0.11% $175.16 18,816 29 Mar 2022 Direct F1, F2
transaction AMED Common Stock Sale $360,977 -2,037 -11% $177.21 16,779 29 Mar 2022 Direct F1, F2, F3
transaction AMED Common Stock Sale $78,805 -443 -2.6% $177.89 16,336 29 Mar 2022 Direct F1, F2, F4
holding AMED Common Stock 506 29 Mar 2022 Through 401(k) Plan F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2 The total amount of shares beneficially owned includes 292 shares held in an employee stock purchase plan account.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.66 to $177.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.66 to $178.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5 The information in this report is based on a plan statement dated as of December 31, 2021.

Remarks:

Chief Legal & Government Affairs Officer